Loading...
•
Dec 31, 2019
Fulcrum Therapeutics Q4 2019 Earnings Report
Fulcrum Therapeutics reported its Q4 and full year 2019 financial results and provided a business update.
Key Takeaways
Fulcrum Therapeutics reported a net loss of $16.1 million for the fourth quarter of 2019, compared to a net loss of $8.9 million for the fourth quarter of 2018. As of December 31, 2019, cash and cash equivalents were $96.7 million.
Observed dose-dependent target engagement in skeletal muscle with losmapimod in Phase 1.
Completed patient enrollment in ReDUX4 Phase 2b trial of losmapimod.
Plan to submit an investigational new drug application (IND) to the U.S. Food and Drug Administration for FTX-6058 in the second half of 2020.
Cash and cash equivalents were $96.7 million as of December 31, 2019.
Fulcrum Therapeutics
Fulcrum Therapeutics
Forward Guidance
The Company expects that its existing cash and cash equivalents will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into the third quarter of 2021.